Reduction of pentylenetetrazol-induced convulsions by the octadecaneuropeptide ODN

Peptides

Volumn 20, Issue 12, 1999, Pages 1431-1436

  Garcia De Mateos Verchere, Juana ^a   Leprince, Jerome ^b   Tonon, Marie Christine ^b   Vaudry, Hubert ^b   Costentin, Jean ^a  

^a Inst Federatif Rech M   (France)

^b INSERM   (France)

Author keywords

DMCM; Endozepines; Flumazenil; Mouse; Octadecaneuropeptide (ODN); Pentylenetetrazol; Seizures

Indexed keywords

4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; BENZODIAZEPINE RECEPTOR; DIAZEPAM BINDING INHIBITOR; FLUMAZENIL; OCTADECANEUROPEPTIDE; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDIOGENIC SEIZURE; CARBOXY TERMINAL SEQUENCE; CLONIC SEIZURE; CONTROLLED STUDY; CONVULSION; LATENT PERIOD; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TONIC SEIZURE; TREATMENT OUTCOME;

ACOUSTIC STIMULATION; AMINO ACID SEQUENCE; ANIMALS; CARBOLINES; CONVULSANTS; DIAZEPAM BINDING INHIBITOR; ELECTRIC STIMULATION; FLUMAZENIL; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; NEUROPEPTIDES; PENTYLENETETRAZOLE; PEPTIDE FRAGMENTS; RECEPTORS, GABA-A; SEIZURES;

EID: 0343415681     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00153-9     Document Type: Article

References (21)

1. Bender A.S., Hertz L. Octadecaneuropeptide (ODN; "anxiety peptide") displaces diazepam more potently from astrocytic than from neuronal binding sites. Eur J Pharmacol. 132:1986;335-336.
2. Berkovich A., McPhie P., Campagnone M., Guidotti A., Hensley P. A natural processing product of rat diazepam binding inhibitor, triakontatetraneuropeptide (diazepam binding inhibitor 17-50) contains an α-helix, which allows discrimination between benzodiazepine binding site subtypes. Mol Pharmacol. 37:1990;164-172.
3. - channels. Regul Pept. 4:1985;33-38.
4. Facklam M., Schoch P., Bonetti E.P., Jenck F., Martin J.R., Moreau J.L., Haefely W.E. Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther. 261:1992;1113-1121.
5. Ferrero P., Guidotti A., Conti-Tronconi B., Costa E. A brain octadeca-neuropeptide generated by tryptic digestion of DBI (diazepam binding inhibitor) functions as a proconflict ligand of benzodiazepine recognition sites. Neuropharmacology. 23:1984;1359-1362.
6. Ferrero P., Santi M.R., Conti-Tronconi B., Costa E., Guidotti A. Study of an octadecaneuropeptide derived from diazepam-binding inhibitor (DBI) biological activity and presence in rat brain . Proc Natl Acad Sci USA. 83:1986;827-831.
7. Garcia De Mateos-Verchere J., Leprince J., Tonon M.C., Vaudry H., Costentin J. The octadecaneuropeptide ODN induces anxiety in rodents possible involvement of a shorter biologically active fragment . Peptides. 19:1998;841-848.
8. Guidotti A., Forchetti C.M., Corda M.G., Konkel D., Bennett C.D., Costa E. Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci USA. 80:1983;3531-3535.
9. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol. 12:1957;12-15.
10. Kavaliers M., Hirst M. An octadecaneuropeptide (ODN) derived from diazepam binding inhibitor increases aggressive interactions in mice. Brain Res. 383:1986;343-349.
11. Leprince J., Gandolfo P., Thoumas J.L., Patte C., Fauchère J.L., Vaudry H., Tonon M.C. Structure-activity relationships of a series of analogues of the octadecaneuropeptide ODN on calcium mobilization in rat astrocytes. J Med Chem. 41:1998;4433-4438.
12. Louiset E., Vaudry H., Cazin L. Allosteric modulation of the GABA-induced chloride current in frog melanotrophs. Ann NY Acad Sci. 680:1993;564-566.
13. Petersen E.N. DMCM a potent convulsive benzodiazepine receptor ligand . Eur J Pharmacol. 94:1983;117-124.
14. Rogawski M.A., Porter R.J. Antiepileptic drugs pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds . Pharmacol Rev. 42:1990;223-286.
15. Seyfried T.N., Glaser G.H. A review of mouse mutants as genetic models of epilepsy. Epilepsia. 26:1985;143-150.
16. A receptor subtypes a role for the neuronal post-translational processing products of rat brain DBI . Biggio G., Costa E. GABA and Benzodiazepine Receptor Subtypes. 1990;51-60 Raven Press, New York.
17. Tonon M.C., Adjeroud S., Lamacz M., Louiset E., Danger J.M., Desrues L., Cazin L., Nicolas P., Vaudry H. Central-type benzodiazepines and the octadecaneuropeptide modulate the effects of GABA on the release of α-melanocyte-stimulating hormone from frog neurointermediate lobe in vitro. Neuroscience. 31:1989;485-493.
18. Tonon M.C., Smih-Rouet F., Lamacz M., Louiset E., Pelletier G., Vaudry H. Endozepines endogenous ligands for benzodiazepine receptors . Med Sci. 10:1994;433-443.
19. Turski L., Stephens D.N., Jensen L.H., Petersen E.N., Meldrum B.S., Patel S., Bondo Hansen J., Löscher W., Schneider H.H., Schmiechen R. Anticonvulsant action of the β-carboline abecarnil studies in rodents and baboon, Papio papio . J Pharmacol Exp Ther. 253:1990;344-352.
20. Vezzani A., Serafini R., Stasi M.A., Samanin R., Ferrarese C. Epileptogenic activity of two peptides derived from diazepam binding inhibitor after intrahippocampal injection in rat. Epilepsia. 32:1991;597-603.
21. Woodbury DM. Convulsant drugs: mechanisms of action. In: Glaser GH, Penry JK, Woodbury DM, editors, Antiepileptic Drugs: Mechanisms of Action, Advances in Neurology. New York: Raven Press, 1980. pp. 294-304.